Lacosamid Hikma

Lacosamide, the active ingredient in Lacosamid Hikma, is an anticonvulsant presented as an intravenous solution for parenteral use. Approved in the EU, it is indicated for the treatment of partial onset seizures in patients with epilepsy, reducing seizure frequency and severity by stabilizing neuronal membranes.\n\nGNH India supplies Lacosamid Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and pharmacies worldwide, ensuring quality and regulatory compliance across markets.

Lacosamid Hikma is an anticonvulsant used in the management of focal seizure disorders.\n\nPartial onset seizures: reduces seizure frequency and severity.\nEpilepsy (adjunctive therapy): improves overall seizure control when added to existing regimens.\nFocal epilepsy: provides additional seizure reduction as part of combination therapy.

Common Side Effects:\n- Dizziness\n- Nausea\n- Fatigue\n- Headache\n\nSerious or Rare Side Effects:\n- Cardiac conduction abnormalities (e.g., PR interval prolongation)\n- Atrial fibrillation\n- Severe skin reactions such as Stevens‑Johnson syndrome\n- Suicidal ideation or behavior

Lacosamid Hikma requires careful clinical monitoring in several situations.\n\nRenal impairment: adjust dosing and monitor renal function.\nCardiac disease: obtain baseline ECG and watch for PR prolongation.\nPregnancy: use only when potential benefit justifies the risk to the fetus.\nConcomitant antiepileptics: monitor for additive central nervous system depression.\nElderly patients: initiate at lower dose and titrate cautiously.\nStore at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lacosamid Hikma may interact with several medications that affect cardiac conduction or drug metabolism.\n\nMajor Interactions (Avoid):\n- Class I antiarrhythmics (e.g., quinidine): increase risk of PR prolongation.\n- Carbamazepine: may lower lacosamide plasma concentrations.\n- Strong CYP2C19 inhibitors (e.g., fluconazole): can raise lacosamide exposure.\n- Other sodium‑channel blockers (e.g., phenytoin): additive CNS effects.\n\nModerate Interactions (Monitor Closely):\n- Alcohol: may enhance dizziness and sedation.\n- Valproate: monitor efficacy and possible increased side effects.\n- Loop diuretics (e.g., furosemide): watch electrolyte balance and cardiac parameters.